Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER – study)

Figures & data

Table 1. Demographics and general clinical characteristics of patients with psoriasis at baseline. Continuous variables were reported as mean (standard deviation (SD)), while categorical variables were expressed as absolute number (percentage).

Characteristic	All patients N = 49
Age (years)	73.1 ± 6.0
≥ 75 years old, N (%)	20 (40.8%)
Sex
Male	28 (57%)
Female	21 (43%)
BMI (kg/m^2)	27.9 ± 4.5
Duration of psoriasis (years)	27.5 ± 16.7
Comorbidities
Psoriatic arthritis	6 (12.2%)
Obesity	14 (28.6%)
Cardiometabolic diseases	35 (71.4%)
Personal history of malignancies	5 (10.2%)
Latent tuberculosis infection	4 (8.1%)
Hepatitis C	2 (4.1%)
Hepatitis B	1 (2.0%)
Others	18 (36.7%)
Special location of psoriasis
Genital	14 (28.6%)
Scalp	15 (30.6%)
Palmo-plantar	8 (16.3%)
Ungual	17 (34.7%)
PASI at baseline	13.6 ± 9.9
≥ 1 Difficult-to-treat areas	26 (53.1%)

Table 2. Previous treatments of psoriasis. Data were expressed as absolute number (percentage).

Previous therapy		22/49 (44.9%)
Previous therapy failure		18/22 (81.8%)
Previous systemic non-biologic therapy	1/22 (4.5%)	Previous systemic biologic therapy	21/22 (95.5%)
Apremilast	1 (4.5%)	Adalimumab	9 (42.8)
		Brodalumab	1 (4.8)
		Etanercept	3 (14.3)
		Infliximab	1 (4.8)
		Ixekizumab	2 (9.5)
		Secukinumab	1 (4.8)
		Ustekinumab	4 (19)
		Patients treated with ≥1 biologic drug	5 (23.8%)

Figure 1. Relative PASI during 28 weeks. Percentage of patients achieving PASI75, PASI90 and PASI100 and absolute PASI ≤2 during the treatment. 4 weeks, N = 47; 16 weeks, N = 45; 28 weeks, N = 40. In cases of N (%) not matching the total in the baseline group, the remainder is attributable to missing data for patients. PASI, Psoriasis Area and Severity Index; PASI75, at least a 75% improvement from baseline in PASI; PASI90, at least a 90% improvement from baseline in PASI. PASI100, 100% improvement from baseline in PASI.

Figure 2. Improvement in mean PASI absolute values over the course of the treatment. Data are represented as mean ± SD; mPASI: mean Psoriasis area severity index.

Table 3. Static genital PGA score (sPGA-G) distribution over time. Data were expressed as absolute number (percentage). In cases of N (%) not matching the total in the baseline group, the remainder is attributable to missing data for patients. sPGA-G, static physician global assessment of Genitalia.

sPGA-G
	Baseline (N = 41)	4-weeks visit (N = 40)	16-weeks visit (N = 38)	24-weeks visit (N = 32)
Clear	27 (65.9%)	26 (65%)	28 (73.7%)	30 (93.8%)
Almost clear	2 (4.9%)	6 (15%)	6 (15.8%)	2 (6.3%)
Mild	5 (12.2%)	5 (12.5%)	3 (7.9%)	0 (0%)
Moderate	5 (12.2%)	2 (5%)	1 (2.6%)	0 (0%)
Severe	2 (4.9%)	1 (2.5%)	0 (0%)	0 (0%)
Very severe	0 (0%)	0 (0%)	0 (0%)	0 (0%)

Table 4. Fingernail PGA score (f-PGA) distribution over time. Data were expressed as absolute number (percentage). In cases of N (%) not matching the total in the baseline group, the remainder is attributable to missing data for patients. F-PGA, fingernail physician global assessment.

f-PGA
	Baseline (N = 42)	4-weeks visit (N = 41)	16-weeks visit (N = 39)	24-weeks visit (N = 34)
Clear	25 (59.5%)	26 (63.4%)	31 (79.5%)	27 (79.4%)
Almost clear	4 (9.5%)	6 (14.6%)	2 (5.1%)	7 (20.6%)
Mild	9 (21.4%)	7 (17.1%)	6 (15.4%)	0 (0%)
Moderate	4 (9.5%)	2 (4.9%)	0 (0%)	0 (0%)
Severe	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Very severe	0 (0%)	0 (0%)	0 (0%)	0 (0%)

Table 5. palmoplantar PGA score (pp-PGA) distribution over time. Data were expressed as absolute number (percentage). In cases of N (%) not matching the total in the baseline group, the remainder is attributable to missing data for patients. pp-PGA, palmoplantar physician global assessment.

pp-PGA
	Baseline (N = 41)	4-weeks visit (N = 40)	16-weeks visit (N = 38)	24-weeks visit (N = 33)
Clear	33 (80.5%)	33 (82.5%)	33 (86.8%)	30 (90.9%)
Almost clear	2 (4.9%)	2 (5.0%)	1 (2.6%)	3 (9.1%)
Mild	3 (7.3%)	4 (10%)	4 (10.5%)	0 (0%)
Moderate	3 (7.3%)	1 (2.5%)	0 (0%)	0 (0%)
Severe	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Very severe	0 (0%)	0 (0%)	0 (0%)	0 (0%)

Table 6. Scalp PGA score (sc-PGA) distribution over time. Data were expressed as absolute number (percentage). In cases of N (%) not matching the total in the baseline group, the remainder is attributable to missing data for patients. sc-PGA, scalp specific physician global assessment.

sc-PGA
	Baseline (N = 41)	4-weeks visit (N = 39)	16-weeks visit (N = 38)	24-weeks visit (N = 32)
Clear	14 (34.1%)	15 (38.5%)	24 (63.2%)	23 (71.9%)
Almost clear	0 (0%)	12 (30.8%)	6 (15.8%)	6 (18.8%)
Mild	12(29.3%)	7 (17.9%)	6 (15.8%)	2 (6.3%)
Moderate	10 (24.4)	3 (7.7%)	1 (2.6%)	1 (3.1%)
Severe	5 (12.2%)	2 (5.1%)	1 (2.6%)	0 (0%)
Very severe	0 (0%)	0 (0%)	0 (0%)	0 (0%)

Data availability statement

Additional data supporting the findings of this study are available from the Corresponding Author on reasonable request.